Holen Sie sich die Stockscreener-App
20.40
4.76%
-1.02
Schlusskurs vom Vortag:
$21.42
Offen:
$21.5
24-Stunden-Volumen:
492.51K
Relative Volume:
0.58
Marktkapitalisierung:
$1.17B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-100.44M
KGV:
-9.1892
EPS:
-2.22
Netto-Cashflow:
$-105.32M
1W Leistung:
-13.30%
1M Leistung:
-16.29%
6M Leistung:
-50.05%
1J Leistung:
-39.82%
1-Tages-Spanne:
$19.89
$22.52
1-Wochen-Bereich:
$19.39
$23.29
52-Wochen-Spanne:
$19.39
$62.74
Structure Therapeutics Inc Adr Stock (GPCR) Company Profile
Firmenname
Structure Therapeutics Inc Adr
Sektor
Branche
Telefon
(628) 229-9277
Adresse
611 GATEWAY BLVD SUITE 223, SOUTH SAN FRANCISCO
Vergleichen Sie GPCR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GPCR
Structure Therapeutics Inc Adr
|
20.40 | 1.17B | 0 | -100.44M | -105.32M | -2.22 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Structure Therapeutics Inc Adr Stock (GPCR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-28 | Eingeleitet | William Blair | Outperform |
| 2025-01-08 | Eingeleitet | Stifel | Buy |
| 2024-12-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-09-23 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-05-21 | Eingeleitet | JP Morgan | Overweight |
| 2024-04-09 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-10-19 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2023-07-27 | Eingeleitet | Piper Sandler | Overweight |
| 2023-05-25 | Fortgesetzt | Jefferies | Buy |
| 2023-02-28 | Eingeleitet | BMO Capital Markets | Outperform |
| 2023-02-28 | Eingeleitet | Guggenheim | Buy |
| 2023-02-28 | Eingeleitet | Jefferies | Buy |
| 2023-02-28 | Eingeleitet | SVB Securities | Outperform |
Alle ansehen
Structure Therapeutics Inc Adr Aktie (GPCR) Neueste Nachrichten
GPCR Stock Hits 52-Week Low at $19.61 Amid Market Challenges - Investing.com Canada
Structure Therapeutics (GPCR) Projected to Post Quarterly Earnings on Friday - Defense World
Research Analysts Issue Forecasts for GPCR Q4 Earnings - Defense World
Q1 Earnings Estimate for GPCR Issued By Leerink Partnrs - Defense World
Structure Therapeutics, Inc.: Strong Pipeline and Financial Stability Underpin Buy Rating Despite Price Target Reduction - TipRanks
Structure Therapeutics Inc ADR’s (NASDAQ: GPCR) Stock Price Continues To Fall - Stocks Register
Leerink cuts Structure Therapeutics target to $60, keeps outperform - Investing.com India
Analysts Set Structure Therapeutics Inc. (NASDAQ:GPCR) Target Price at $81.29 - Defense World
Structure Therapeutics (NASDAQ:GPCR) Research Coverage Started at William Blair - Defense World
Heron Therapeutics’ (HRTX) Buy Rating Reiterated at Needham & Company LLC - Defense World
Structure Therapeutics (NASDAQ:GPCR) Coverage Initiated by Analysts at William Blair - MarketBeat
Structure Therapeutics Advances in Obesity Treatment Pipeline - TipRanks
Structure Therapeutics (NASDAQ:GPCR) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPS - MarketBeat
Structure Therapeutics (NASDAQ:GPCR) Shares Up 8% on Earnings Beat - MarketBeat
Structure Therapeutics, Inc.: Promising Outlook with Aleniglipron in Obesity Treatment and Strategic Advancements Justify Buy Rating - TipRanks
Promising Potential of Structure Therapeutics’ Aleniglipron: A Compelling Buy Recommendation - TipRanks
JMP cuts Structure Therapeutics price target to $87 - Investing.com
Structure Therapeutics Inc. (NASDAQ:GPCR) Receives $81.29 Average Price Target from Brokerages - MarketBeat
Buy Rating for Structure Therapeutics: Promising Phase 2b Trials and Strong Financial Position - TipRanks
Structure Therapeutics (NASDAQ:GPCR) Hits New 52-Week LowTime to Sell? - MarketBeat
Structure Therapeutics reports Q4 net loss $36.5M vs. net loss $24.5M last year - TipRanks
Structure Therapeutics (NASDAQ:GPCR) Trading Down 6.4%Time to Sell? - MarketBeat
Structure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Highlights - The Manila Times
Can Structure Therapeutics' Obesity Drug Challenge Wegovy? Trial Enrollment Complete - StockTitan
GPCR stock touches 52-week low at $20.11 amid market challenges By Investing.com - Investing.com South Africa
GPCR stock touches 52-week low at $20.11 amid market challenges - Investing.com India
Structure Therapeutics (NASDAQ:GPCR) Trading Up 6.2%Here's Why - MarketBeat
Handelsbanken Fonder AB Purchases Shares of 165,000 Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat
Structure Therapeutics Inc. (NASDAQ:GPCR) Sees Large Decline in Short Interest - MarketBeat
GPCR Stock Hits 52-Week Low at $23.48 Amid Market Challenges - Investing.com Canada
Structure Therapeutics (NASDAQ:GPCR) Sets New 52-Week Low – Here’s What Happened - Defense World
Why Structure Therapeutics Stock Was Stumbling This Week - The Globe and Mail
abrdn plc Sells 45,695 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat
Financial Fitness Check: Examining Structure Therapeutics Inc ADR (GPCR)’s Key Ratios - The Dwinnex
Spire Wealth Management Acquires Shares of 8,949 Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat
Structure Therapeutics (NASDAQ:GPCR) Trading Down 6.7%Should You Sell? - MarketBeat
HSBC Securities Downgrades Morgan Stanley (MS) to a Hold from a Buy - Knox Daily
JD.com Inc ADR (JD) receives an Outperform rating from Bernstein - Knox Daily
Ratio Examination: Bausch Health Companies Inc (BHC)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Brokerages Set Structure Therapeutics Inc. (NASDAQ:GPCR) PT at $81.29 - MarketBeat
Understanding the Recent Fluctuations of Structure Therapeutics Inc ADR’s (GPCR) Stock - The News Heater
Structure Therapeutics Inc. (NASDAQ:GPCR) Short Interest Update - MarketBeat
CCG Wealth Management LLC Makes New $4.07 Million Investment in Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat
Analysts Set Structure Therapeutics Inc. (NASDAQ:GPCR) PT at $81.29 - Defense World
GLP-1 Agonists Weight Loss Drugs Market Size Report, 2030 - Grand View Research
Short Interest in Structure Therapeutics Inc. (NASDAQ:GPCR) Rises By 5.8% - Defense World
Finanzdaten der Structure Therapeutics Inc Adr-Aktie (GPCR)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.39%
0.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):